Loading...
•
Mar 31
Cerus Q1 2025 Earnings Report
Cerus Corporation announced its financial results for the first quarter ended March 31, 2025, reporting an increase in product revenue and total revenue compared to the prior year.
Key Takeaways
Cerus Corporation delivered a strong start to 2025, with first quarter product revenue increasing by 13% to $43.2 million and total revenue reaching $48.9 million. The company also achieved a positive non-GAAP adjusted EBITDA and reiterated its full-year 2025 product revenue guidance.
First quarter 2025 product revenue increased by 13% to $43.2 million compared to the prior year.
Total revenue for the first quarter of 2025 was $48.9 million, including $5.6 million in government contract revenue.
Non-GAAP adjusted EBITDA for the first quarter of 2025 was positive $0.2 million, an improvement from a negative $2.7 million in the prior year.
The company reiterated its full-year 2025 product revenue guidance range of $194 million to $200 million.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEurope, Middle East and Africa Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Cerus Corporation expects full-year 2025 product revenue to be in the range of $194 million to $200 million, reflecting 8% to 11% growth from 2024. This includes IFC revenue guidance between $12 million to $15 million.
Positive Outlook
- Continued penetration with U.S. platelet customers is expected to fuel product revenue growth.
- Geographic expansion of the INTERCEPT platelet business is anticipated.
- Increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the U.S. is a key driver.
- The company aims to deliver operating cash flow to fuel growth and make INTERCEPT the standard of care globally.
- Received CE Mark for the INT200, the next-generation LED-based illumination device, ahead of plan.
Challenges Ahead
- Risks associated with commercialization and market acceptance of the INTERCEPT Blood System.
- Uncertainty regarding the volume or timing of commercial purchases from U.S. customers.
- Potential inability to obtain regulatory approval for pipeline programs or new product offerings in a timely manner.
- Macroeconomic developments, including military conflicts, rising interest rates, inflation, and trade tensions, could negatively impact business operations.
- Risks related to maintaining an effective and qualified U.S.-based commercial organization.
Revenue & Expenses
Visualization of income flow from segment revenue to net income